Leerink Partnrs Brokers Lift Earnings Estimates for EW

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Investment analysts at Leerink Partnrs raised their Q4 2025 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a research report issued to clients and investors on Wednesday, April 16th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings per share of $0.64 for the quarter, up from their previous estimate of $0.63. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' FY2029 earnings at $4.19 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%.

A number of other analysts also recently weighed in on the stock. Truist Financial decreased their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Hold" and a consensus target price of $78.55.

Edwards Lifesciences Stock Down 3.2 %

EW traded down $2.30 on Thursday, reaching $69.23. The company's stock had a trading volume of 3,546,323 shares, compared to its average volume of 4,629,837. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $95.25. The business's 50 day moving average is $71.31 and its 200 day moving average is $70.92. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market cap of $40.70 billion, a price-to-earnings ratio of 9.93, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,853 shares of company stock valued at $5,163,062. Company insiders own 1.29% of the company's stock.

Institutional Trading of Edwards Lifesciences

A number of large investors have recently added to or reduced their stakes in the business. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $26,000. Vega Investment Solutions purchased a new position in Edwards Lifesciences in the 4th quarter worth about $27,000. Millstone Evans Group LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $29,000. Global X Japan Co. Ltd. lifted its stake in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after buying an additional 216 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $30,000. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.